Publikationen 2017

Albers P.
PSA screening - for whom and when?
Asian J Androl. 2017 Sep 5.
doi: 10.4103/aja.aja_37_17. [Epub ahead of print] PubMed PMID: 28879867.

Albers P.
Surveillance of Patients with Clinical Stage I Testis Cancer is Safe and Will Remain Unchanged.
Eur Urol. 2017 Jan;71(1):130-131.
doi: 10.1016/j.eururo.2016.10.035. Epub 2016 Nov 1. PubMed PMID: 27815084.

Albers P.
Retroperitoneale Residualtumorresektion nach Chemotherapie maligner  Hodentumoren.
Aktuelle Urol. 2017 Feb;48(1):79-87.
doi: 10.1055/s-0042-116574. Epub 2017 Apr 12. German. PubMed PMID: 28403497.

Albers P.
Re: Reevaluating PSA Testing Rates in the PLCO Trial.
Eur Urol. 2017 Feb;71(2):300.
doi: 10.1016/j.eururo.2016.10.039. Epub 2016 Nov 4. PubMed PMID: 27823819.

Albers P, Bokemeyer C.
Testis cancer: some problems still remain unsolved.
World J Urol. 2017 Aug;35(8):1159-1160.
doi: 10.1007/s00345-017-2041-5. Epub 2017 May 16. PubMed PMID: 28509970.

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Pal SK, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Belmunt J, Galsky MD; RISC Investigators.
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC).
Ann Oncol. 2017 Oct 25.
doi: 10.1093/annonc/mdx692. [Epub ahead of print] PubMed PMID: 29077785.

Boormans JL, Mayor de Castro J, Marconi L, Yuan Y, Laguna Pes MP, Bokemeyer C, Nicolai N, Algaba F, Oldenburg J, Albers P.
Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel.
Eur Urol. 2017 Nov 20. pii: S0302-2838(17)30826-6.
doi: 10.1016/j.eururo.2017.09.025. [Epub ahead of print] Review. PubMed PMID: 29100813.

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
Acta Oncol. 2017 Aug 30:1-7.
doi: 10.1080/0284186X.2017.1369565. [Epub ahead of print] PubMed PMID: 28853615.

Droop J, Szarvas T, Schulz WA, Niedworok C, Niegisch G, Scheckenbach K, Hoffmann MJ.
Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma.
PLoS One. 2017 Apr 21;12(4):e0176287.
doi: 10.1371/journal.pone.0176287. eCollection 2017. PubMed PMID: 28430799; PubMed Central PMCID: PMC5400278.

Esch LH, Fahlbusch M, Albers P, Hautzel H, Müller-Mattheis V.
11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer.
BJU Int. 2017 Sep;120(3):337-342.
doi: 10.1111/bju.13706. Epub 2016 Dec 5. PubMed PMID: 27860163.

Fischer S, Tandstad T, Wheater M, Porfiri E, Fléchon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Lorch A, Dieckmann KP, Cohn-Cedermark G, Ståhl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Gillessen S.
Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.
J Clin Oncol. 2017 Jan 10;35(2):194-200.
Epub 2016 Nov 28. PubMed PMID: 27893332.

Giessing M, Albers P.
Korporoplastik bei Induratio penis plastica (IPP, Peyronie’s Disease).
Aktuelle Urol. 2017 May;48(3):256-262.
doi: 10.1055/s-0041-108887. Epub 2017 Jun 14. German. PubMed PMID: 28614885.

Hölscher AS, Schulz WA, Pinkerneil M, Niegisch G, Hoffmann MJ.
Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Clin Epigenetics. 2018 Jan 4;10:1.
doi: 10.1186/s13148-017-0434-3. eCollection 2018. PubMed PMID: 29312470; PubMed Central PMCID: PMC5755363.

Isono M, Hoffmann MJ, Pinkerneil M, Sato A, Michaelis M, Cinatl J Jr, Niegisch G, Schulz WA
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
J Exp Clin Cancer Res. 2017 Jan 3;36(1):1.
doi: 10.1186/s13046-016-0473-1. PubMed PMID: 28049532; PubMed Central PMCID: PMC5209915.

Janssen M, Putz J, Giessing M, Fornara P, Friedersdorff F, Dreikorn K, Heynemann H, Stein K, Wunderlich H, Stöckle M.
[Report of the 23rd annual meeting of the Working Group Kidney Transplantation of the German Society of Urology in Homburg (Saar)].
Urologe A. 2017 Jan;56(1):69-71.
doi: 10.1007/s00120-016-0295-y. German. PubMed PMID: 27966097

Kirchner J, Schaarschmidt BM, Sawicki LM, Heusch P, Hautzel H, Ermert J, Rabenalt R, Antoch G, Buchbender C.
Evaluation of Practical Interpretation Hurdles in 68Ga-PSMA PET/CT in 55 Patients: Physiological Tracer Distribution and Incidental Tracer Uptake.
Clin Nucl Med. 2017 Jul;42(7):e322-e327.
doi: 10.1097/RLU.0000000000001672. PubMed PMID: 28481787

Koutsogiannouli EA, Wagner N, Hader C, Pinkerneil M, Hoffmann MJ, Schulz WA
Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells.
Int J Mol Sci. 2017 Jul 5;18(7). pii: E1449.
doi: 10.3390/ijms18071449. PubMed PMID: 28678170; PubMed Central PMCID: PMC5535940.

Lorch A, Beyer J.
How we treat germ cell cancers.
Cancer. 2017 Jun 15;123(12):2190-2192.
doi: 10.1002/cncr.30751. Epub 2017 May 17. PubMed PMID: 28513824.

Lorch A, Beyer J.
High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how.
World J Urol. 2017 Aug;35(8):1177-1184.
doi: 10.1007/s00345-016-1941-0. Epub 2016 Sep 27. PubMed PMID: 27678272.

Lusch A, Albers P.
Residual tumor resection (RTR).
World J Urol. 2017 Aug;35(8):1185-1190.
doi: 10.1007/s00345-016-1984-2. Epub 2016 Dec 21. PubMed PMID: 28004146.

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium Group.
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.
Clin Genitourin Cancer. 2017 Nov 1. pii: S1558-7673(17)30318-X.
doi: 10.1016/j.clgc.2017.10.012. [Epub ahead of print] PubMed PMID: 29158079.

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
Eur Urol Focus. 2017 Mar 31. pii: S2405-4569(17)30079-2.
doi: 10.1016/j.euf.2017.03.011. [Epub ahead of print] PubMed PMID: 28753879; PubMed Central PMCID: PMC5626651.

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group.
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.
Eur Urol Focus. 2017 Jun 3. pii: S2405-4569(17)30125-6.
doi: 10.1016/j.euf.2017.05.006. [Epub ahead of print] PubMed PMID: 28753897; PubMed Central PMCID: PMC5712487.

Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators.
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Eur Urol. 2017 Feb;71(2):281-289.
doi: 10.1016/j.eururo.2016.09.042. Epub 2016 Oct 8. PubMed PMID: 27726966; PubMed Central PMCID: PMC5576985.

Niegisch G, Albers P.
Targeting mTOR in urothelial cancer-Beating a dead horse or ready for prime time?
Urol Oncol. 2017 Oct;35(10):600-601.
doi: 10.1016/j.urolonc.2017.07.001. Epub 2017 Jul 31. PubMed PMID: 28774722.

Niegisch G.
[Urothelial cancer: update on systemic treatment options].
Aktuelle Urol. 2017 Aug;48(4):340-349.
doi: 10.1055/s-0043-107040. Epub 2017 Jun 20. German. PubMed PMID: 28633191.

Nini A, Konieczny M, Winter C, Lusch A, Krauspe R, Albers P.
Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series.
Urol Oncol. 2017 Nov 9. pii: S1078-1439(17)30553-7.
doi: 10.1016/j.urolonc.2017.10.016. [Epub ahead of print] PubMed PMID: 29129354.

Ohlmann CH, Goebell PJ, Grimm MO, Klier J, König F, Machtens S, Schostak M, Schrader AJ, Albers P.
[Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
Urologe A. 2017 Dec;56(12):1597-1602.
doi: 10.1007/s00120-017-0459-4. Review. German. PubMed PMID: 28695241.

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I, Théodore C, Grande E, Shen X, Wang J, Nelson B, Derleth CL, van der Heijden MS.
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31015-1.
doi: 10.1016/j.eururo.2017.11.023. [Epub ahead of print] PubMed PMID: 29273410.

Pinkerneil M, Hoffmann MJ, Schulz WA, Niegisch G.
HDACs and HDAC inhibitors in urothelial carcinoma - perspectives for an antineoplastic treatment.
Curr Med Chem. 2017 Jan 11. [Epub ahead of print]
PubMed PMID: 28078999.

Pixberg CF, Raba K, Müller F, Behrens B, Honisch E, Niederacher D, Neubauer H, Fehm T, Goering W, Schulz WA, Flohr P, Boysen G, Lambros M, De Bono JS, Knoefel WT, Sproll C, Stoecklein NH, Neves RPL.
Analysis of DNA methylation in single circulating tumor cells.
Oncogene. 2017 Jun 8;36(23):3223-3231.
doi: 10.1038/onc.2016.480. Epub 2017 Jan 9. PubMed PMID: 28068321.

Pérez-Lanzac A, Parra-Serván P, León-Delgado C, Okhunov Z, Lusch A, Álvarez-Ossorio JL.
Combination of extracorporeal lithotripsy and flexible ureterorenoscopy optimize renal lithiasis therapy.
Actas Urol Esp. 2017 Apr;41(3):200-204.
doi: 10.1016/j.acuro.2016.08.002. Epub 2016 Sep 5. English, Spanish. PubMed PMID: 27609350.

Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY; RISC Investigators.
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Cancer Med. 2017 Jan;6(1):186-194.
doi: 10.1002/cam4.986. Epub 2016 Dec 20. PubMed PMID: 28000388; PubMed Central PMCID: PMC5269690.

Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, Agarwal N, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY; RISC Investigators.
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.
Clin Genitourin Cancer. 2017 Aug 24. pii: S1558-7673(17)30242-2.
doi: 10.1016/j.clgc.2017.08.001. [Epub ahead of print] PubMed PMID: 28923700.

Rößing L, Giessing M.
Operative Therapie der kongenitalen und erworbenen Penisdeviation mittels Raffplastik.
Aktuelle Urol. 2017 May;48(3):252-255.
doi: 10.1055/s-0043-109439. Epub 2017 Jun 14. German. PubMed PMID: 28614884.

Sawicki LM, Buchbender C, Boos J, Giessing M, Ermert J, Antke C, Antoch G, Hautzel H.
Diagnostic potential of PET/CT using a (68)Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):102-107. Epub 2016 Mar 21.
PubMed PMID: 26996777

Schlütermann D, Skowron MA, Berleth N, Böhler P, Deitersen J, Stuhldreier F, Wallot-Hieke N, Wu W, Peter C, Hoffmann MJ, Niegisch G, Stork B.
Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
Urol Oncol. 2017 Dec 21. pii: S1078-1439(17)30609-9.
doi: 10.1016/j.urolonc.2017.11.021. [Epub ahead of print] PubMed PMID: 29276062.

Schmid SC, Sathe A, Guerth F, Seitz AK, Heck MM, Maurer T, Schwarzenböck SM, Krause BJ, Schulz WA, Stoehr R, Gschwend JE, Retz M; German Bladder Cancer Network, Nawroth R.
Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin.
Urol Oncol. 2017 Sep;35(9):544.e1-544.e10.
doi: 10.1016/j.urolonc.2017.04.015. Epub 2017 May 10. PubMed PMID: 28501564.

Schulz WA.
Does HERV-K represent a potential therapeutic target for prostate cancer?
Expert Opin Ther Targets. 2017 Oct;21(10):921-924.
doi: 10.1080/14728222.2017.1373095. Epub 2017 Aug 30. PubMed PMID: 28847189.

Schulz WA, Kramer MW, Fuessel S, Stöhr R, Hoffmann MJ, Nawroth R.
[The 6^th symposium of the German Association for Bladder Cancer Research].
Urologe A. 2017 Jun;56(6):806-807.
doi: 10.1007/s00120-017-0405-5. German. PubMed PMID: 28466114.

Seidel C, Oechsle K, Lorch A, Dieing A, Hentrich M, Hornig M, Grünwald V, Cathomas R, Meiler J, de Wit M, Bokemeyer C.
Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Urol Oncol. 2016 Apr;34(4):167.e21-8.
doi: 10.1016/j.urolonc.2015.11.007. Epub 2015 Dec 11. PubMed PMID: 26699830.

Skowron MA, Sathe A, Romano A, Hoffmann MJ, Schulz WA, van Koeveringe GA, Albers P, Nawroth R, Niegisch G.
Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma.
Urol Oncol. 2017 Sep;35(9):544.e11-544.e23.
doi: 10.1016/j.urolonc.2017.05.003. Epub 2017 May 25. PubMed PMID: 28551413

Skowron MA, Niegisch G, Albrecht P, van Koeveringe G, Romano A, Albers P, Schulz WA, Hoffmann MJ.
Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines.
Int J Mol Sci. 2017 Aug 2;18(8). pii: E1680.
doi: 10.3390/ijms18081680. PubMed PMID: 28767070; PubMed Central PMCID: PMC5578070.

Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT, Hanna NH, Albany C, Foster R, Cedermark GC, Feldman DR, Powles T, Lewis MA, Grimison PS, Bank D, Porter C, Albers P, De Santis M, Srinivas S, Bosl GJ, Nichols CR.
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.
J Clin Oncol. 2017 Nov 1;35(31):3525-3528.
doi: 10.1200/JCO.2017.73.4723. Epub 2017 Aug 30. PubMed PMID: 28854068.

Ullrich T, Quentin M, Schmaltz AK, Arsov C, Rubbert C, Blondin D, Rabenalt R, Albers P, Antoch G, Schimmöller L.
Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate.
Eur Radiol. 2018 Jan;28(1):17-23.
doi: 10.1007/s00330-017-4940-7. Epub 2017 Jul 7. PubMed PMID:  28687912.

Ullrich T, Schimmöller L, Oymanns M, Blondin D, Dietzel F, Kirchner J, Arsov C, Rabenalt R, Albers P, Antoch G, Quentin M.
Current Utilization and Acceptance of Multiparametric MRI in the Diagnosis of Prostate Cancer. A Regional Survey.
Rofo. 2017 Sep 21.
doi: 10.1055/s-0043-118128. [Epub ahead of print] PubMed PMID:  28934811.

Ullrich T, Quentin M, Arsov C, Schmaltz AK, Tschischka A, Laqua N, Hiester A, Blondin D, Rabenalt R, Albers P, Antoch G, Schimmöller L.
Risk Stratification of Equivocal Lesions in Multiparametric Magnetic Resonance Imaging of the Prostate.
J Urol. 2017 Sep 20. pii: S0022-5347(17)77559-3.
doi: 10.1016/j.juro.2017.09.074. [Epub ahead of print] PubMed PMID:  28941924.

Ullrich T, Quentin M, Oelers C, Dietzel F, Sawicki LM, Arsov C, Rabenalt R, Albers P, Antoch G, Blondin D, Wittsack HJ, Schimmöller L.
Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: A prospective comparison study of image quality.
Eur J Radiol. 2017 May;90:192-197.
doi: 10.1016/j.ejrad.2017.02.044. Epub 2017 Mar 4. PubMed PMID:  28583633.